Thursday, September 10, 2026
'Iran routed up to $2.5 billion via China sanctions workaround in past year - Reuters'
Iran routed an estimated $2 billion to $2.5 billion through a China-based trade mechanism over the past year, using proceeds from oil sales to pay for Chinese goods and, at least once, contracts for military equipment, Reuters reported on Thursday.
The barter-like arrangement allowed Tehran to turn payments for Iranian oil into credits for Chinese imports without sending money directly through international banking channels, Reuters said, citing two senior Iranian sources and three other people familiar with the mechanism.
Iran used the system to buy medicines, vehicles and communications equipment, while it was also used in connection with contracts worth millions of dollars to supply Iran with air defense equipment over the past year, the sources said.
Billions routed outside normal banking channels
The mechanism has been operating since at least 2021 but has become more important as Washington tightened sanctions on Iran and companies doing business with Tehran, according to the report.
A buyer acting on behalf of Chinese state-owned oil trader Zhuhai Zhenrong had, at least until this year, deposited hundreds of millions of dollars a month with a China-based financial entity known as ChuXin, three people familiar with the arrangement told Reuters.
Those payments covered Iranian oil purchases. ChuXin then sent funds to Chinese exporters and companies involved in infrastructure projects in Iran, likely through other Chinese financial institutions, Reuters reported.
Around 70% of the Iranian oil proceeds handled through the arrangement went to infrastructure projects, while the rest entered accounts belonging to a special purpose vehicle, or SPV, used to pay suppliers of goods to Iran, the sources said.
The two Iranian sources confirmed the existence of the SPV, which Reuters said had not previously been reported.
Oil exchanged for access to Chinese goods
The SPV is managed by two entities, one acting on behalf of China's Ministry of Commerce and another linked to Iran's central bank, according to all five sources.
When Iran's central bank approves an importer to use funds held in the SPV, the Iran-linked entity informs its Chinese counterpart so payments can be made to suppliers, three of the sources said.
The structure gives Chinese manufacturers access to payment without dealing directly with Iran, according to the report. Reuters said there was no indication that the Chinese manufacturers supplying civilian goods had broken sanctions.
Reuters could find no record of a financial institution called ChuXin in Chinese corporate registries, and one source said it may exist only on a spreadsheet.
China says unaware of arrangement
China's foreign ministry told Reuters it was "not familiar with the situation you describe" when asked about the mechanism.
"China has consistently opposed unilateral sanctions that have no basis in international law and have not been authorized by the United Nations Security Council," the ministry said.
Iran's UN missions in New York and Geneva did not respond to Reuters requests for comment. Iran's central bank, China's commerce ministry, the National Iranian Oil Company and Zhuhai Zhenrong also did not respond to questions about their reported roles.
US pressure raises stakes
China has long been the main buyer of Iranian oil. More than 80% of Iran's shipped crude went to China in 2025, averaging around 1.4 million barrels per day, according to Kpler data cited by Reuters.
The arrangement has helped Tehran keep trade flowing despite years of sanctions, while giving China access to discounted Iranian crude.
Its importance has grown as the United States has increased economic pressure on Iran during the six-month-old war. Treasury Secretary Scott Bessent warned countries in August to cut business ties with Tehran or risk losing access to the dollar-based financial system.
Reuters said it could not determine how the US naval blockade on Iranian oil exports had affected the China trade mechanism. No Iranian crude cargoes had successfully passed through the Strait of Hormuz to China since the blockade was reinstated on July 14, according to the news agency.
A UN embargo on exports of most major conventional weapons to Iran was restored in September 2025 along with other sanctions.
Andrea Ghiselli, an international politics lecturer at the University of Exeter who studies China's relations with the Middle East, told Reuters that Beijing wanted to resist US pressure without putting major Chinese banks and companies at risk of exclusion from the international financial system.
"They want plausible deniability," he said.
Wednesday, September 9, 2026
AMA releases CPT 2027 code set with 299 new codes, 10 for AI
The American Medical Association released its 2027 Current Procedural Terminology (CPT) code set Sept. 9, an update that adds 299 codes and continues to build out billing for clinical AI.
The set takes effect Jan. 1 and carries 453 total editorial changes: 299 new codes, 74 revisions and 80 deletions, the AMA said.
Ten of the new codes describe AI-related services, raising the total number of AI-related CPT codes to 43. The AMA also updated Appendix S, its taxonomy that sorts medical AI by how much of the work the machine does — assistive, augmentative or autonomous — and guides how new tools get coded.
“As new technologies and clinical approaches emerge, the nation’s health system needs a reliable way to describe the care physicians provide,” said AMA President Willie Underwood III, MD. Dr. Underwood said a physician-led coding system gives that work “unmatched scale, expertise and legitimacy.”
The set’s key clinical change, released in August, is a maternity coding overhaul that retires the decades-old global maternity bundle in favor of separate reporting across antepartum, labor, delivery and postpartum care.
Other 2027 updates span several service lines:
- Ventricular assist devices: three new codes, including for left ventricular assist devices, plus revised guidelines.
- Hernia repair: nine new codes for open, laparoscopic and thoracoscopic diaphragmatic repairs.
- Sleep medicine: six new codes for unattended sleep studies, including tests delivered outside traditional sleep centers.
- Prostate biopsy, biofeedback and radiology: updated codes, including a new time-based biofeedback structure and a new head and neck magnetic resonance angiography table.
For revenue cycle and physician leaders, the changes reset documentation and coding workflows across several service lines at once. The growing AI code library also signals that payers and providers are inching toward a shared way to bill for algorithmic tools that still largely lack one — 43 codes now, up from a handful a few years ago.
AI-Designed Drug Just Moved Six Different Aging Clocks At Once
An experimental drug designed using AI has produced measurable shifts toward a younger biological-age profile in patients.
Developed by Insilico Medicine, the drug - rentosertib - was initially engineered to treat idiopathic pulmonary fibrosis (IPF), a progressive, age-associated lung-scarring disease. When researchers analyzed blood samples from a Phase IIa clinical trial, they applied six proteomic profiling "aging clocks" among 42 participants. All six detected reductions in predicted biological age, whereas the placebo group showed little change or slight increases. The most pronounced and consistent effects emerged around week four of treatment.
The study was authored by Insilico with academic collaborators from Harvard, Stanford, the Broad Institute, RWTH Aachen, Peking University and Westlake University.
Insilico used AI not only to identify a specific enzyme (TNIK) linked to both fibrosis and aging pathways, but also to generate and optimize the specific molecule designed to inhibit it. That dual application makes rentosertib a rare clinical test of AI uncovering a target case and building new therapeutics from scratch.
In the earlier Phase IIa, patients in the 60mg once-daily arm recorded a mean improvement in forced vital capacity of 98.4 milliliters against a mean decline of 20.3 milliliters on placebo. FVC declines with age in healthy people over 65 at roughly 20 to 50 milliliters a year, which is why Insilico treats it as a physiological aging marker as well as an efficacy endpoint.
"If you manage to add 3 years to everyone's life, the drug should be able to significantly extend the healthy portion of life as well, translating into trillions of dollars in productivity and savings," said Alex Zhavoronkov, Insilico's founder and co-CEO.
And according to 2013 chemistry Nobel laureate Michael Levitt, "What convinces me is not the size of the effect but the agreement, because these models share neither their features nor their training data," he said of the six clocks reaching the same conclusion on the same 42 patients.
Rentosertib is no longer confined to early-stage laboratory work. In July, Insilico announced that the drug had entered a randomized Phase III trial, expected to enroll 320 IPF patients for a 52-week, once-daily regimen. That trial is designed to evaluate pulmonary-fibrosis efficacy and safety, not life extension - but it advances an AI-generated molecule into the final phase of clinical development. Of note - the study does not prove that rentosertib extends human lifespan or literally shaves years off a patient's age. But the clock results, the senescence and metabolic pathway shifts, and the dose-dependent FVC gains all point the same way, and more study is needed to understand the possibilities.
If the drug succeeds clinically, it validates AI-driven drug discovery, and offers a template for testing future medicines against both specific age-related diseases and the biomarkers of aging itself. If it fails in Phase III, the aging clocks will have been measuring a lung.
https://www.zerohedge.com/medical/ai-designed-drug-just-moved-six-different-aging-clocks-once
Subscribe to:
Posts (Atom)